Webinars

Exploring Alternatives to Antibodies: Evaluation of Aptamer Affinity Enrichment for Mass Spectrometry

Eric Kuhn from the Broad Institute of Harvard and MIT gave his presentation on how he used SOMAmers to evaluate proteomic profiles discovered using the SOMAscan assay to study cardiovascular disease.

View Here 

Modified Aptamer-Based Proteomic Profiling for Predicting Early Mortality in Heart Failure Patients

Dr. Florence Pinet of the Pasteur Institute of Lille, France, gave a presentation on her work with the SOMAscan assay to find predictive protein biomarkers for early mortality in heart failure patients.

View Here 

SOMAmer Reagents: Specific and Versatile Protein Affinity Reagents

With unique amino-acid like modifications, SOMAmer reagents possess the strong binding affinities and high target specificities of antibodies. Since SOMAmer reagents are manufactured using traditional DNA chemical synthesis, they have the advantage of lot-to-lot consistency and superior thermal stability desired for reproducible and robust assay performance. Attendees will develop an appreciation of the benefits and limitations of the SOMAmer reagents by drawing comparisons to more traditional affinity reagents such as antibodies.

View Here 

This course will provide an overview of the specificity of protein-binding reagents in general, and more in-depth information regarding SOMAmer® (Slow Off-rate Modified Aptamers) Reagents. Course attendees will develop an appreciation of approaching hypothesis-free biomarker discovery with SOMAmers, as well as the use of SELEX in identifying reagents that are highly specific for closely related proteins.

View Here 

Probing Exosomes Using Novel Affinity-Based Proteomic Technology

In this webinar, Aled Clayton, Ph.D., principal investigator within the tumor immunology group at the Institute of Cancer and Genetics for Cardiff University School of Medicine, will describe his novel approach to examining the intricate composition of exosomes and how his technique may be applied to clinical diagnostics.

View Here 

Integrating Metabolomic and Proteomic Profiles for ‘Less Impersonal’ Medicine

In this on-demand webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.

View Here 

Bound for Success: Powerful New Affinity Reagents for Multiple Applications

In this symposium, participants will gain a better understanding of the science behind SomaLogic’s “next generation” of  protein binding reagents (SOMAmers – Slow Off-rate Modified Aptamers). Through discussion and visualizations, participants will learn how protein-like modifications to nucleic-acid ligands lead to superior protein-binding reagents with slow off-rates, and high binding affinities. The specific structural features of SOMAmer-protein interactions will be discussed via presentation of co-crystal structures of several SOMAmers in complex with their protein targets

View Here 

The Art, Science And Discipline Of Biomarker Study And Program Design

Biomarkers serve a key role in fingerprinting changes throughout the body; biologic changes such as cancer development, onset of metabolic disease, the effects of pharmacology, nutrition, or even risk of future heart attack or stroke. Unfortunately, many apparently interesting biomarker discoveries fail to replicate or translate into products or productivity because the discipline of biomarker study and program design is not sufficiently respected This symposium will illustrate how to optimally design fit-for-purpose biomarker studies with appropriate attention to false discovery rates, the existence of truth standards and the nature and weight of evidence required for the context of use.

View Here 

We have analyzed the proteomics of >8000 blood and tumor tissue samples to discover diagnostic, prognostic and mechanistic biomarkers of malignancy. In this symposium we will present case studies highlighting significant advances in biomarker validation for malignant mesothelioma, lung cancer and pancreatic cancer. Clinical experts in each field will discuss study design, proteomic analysis, test performance and clinical utility for diagnosis, prognosis and treatment.

View Here